Clinical Trial

Study to Evaluate the Efficacy and Safety of Adjuvant Tislelizumab in High-Risk Stage I NSCLC

Name: Study to Evaluate the Efficacy and Safety of Adjuvant Tislelizumab in High-Risk Stage I NSCLC — clinical trial record (NCT07120282)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

A Randomized, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Adjuvant Tislelizumab in High-Risk Stage I NSCLC

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2025-08-06.

Status change: Not Yet Recruiting → Recruiting 2026-03-05

Trial Details

NCT Number	NCT07120282
Lead Sponsor	Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Conditions	Lung Cancer (NSCLC)
Enrollment	108 participants
Start Date	2025-10-28
Primary Completion	2029-08-15 (estimated)
Study Completion	2030-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-03-09